Key result
S-ICD SMART Pass deactivation unmasks a 22-second asystolic pause in hypertrophic cardiomyopathy.
Case Report (n=1)
SMART Pass deactivation in an S-ICD can record underlying asystole, emphasizing the importance of reviewing deactivation events for bradyarrhythmias.
Answers are grounded in this paper and cite their sources.
Clinicians should review S-ICD SMART Pass deactivations for occult asystole; this single case leaves open fibrosis as a bradyarrhythmia driver in non-obstructive HCM.
Background The SMART Pass (SP) algorithm of the subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific Emblem) uses a high pass filter to reduce inappropriate shocks due to signal oversensing. In cases of small to none R-wave amplitude the SP algorithm is automatically deactivated and an electrocardiogram (ECG) is recorded. Case Summary A 63-year-old patient with hypertrophic cardiomyopathy (HCM) without left ventricular outflow tract obstruction underwent implantation of an S-ICD. When the patient reported syncope months later device interrogation revealed SP deactivation due to a 22-second asystole, consistent with the timing of the syncope. Prior to the event, there was no indication of future pacing requirement. The patient had a stable two-vessel coronary artery disease as well as unaltered echocardiographic findings including preserved left ventricular ejection fraction. The S-ICD was replaced by a transvenous dual-chamber implantable cardioverter-defibrillator. Discussion Although bradycardia detection is not available in the S-ICD system, in our case it was enabled due to ECG recording performed during SP deactivation, which outlines the importance of careful investigation. Since bradyarrhythmia in HCM is considered rare it has been studied far less extensively than atrial and ventricular tachyarrhythmia. There is substantial evidence that myocardial fibrosis is a significant predictor of ventricular tachycardia and sudden cardiac death. However more extended research is required to further investigate the association between myocardial fibrosis and bradyarrhythmia in patients with HCM as well as to evaluate the potential of Magnetic Resonance Imaging-based screening to identify patients at risk requiring future pacing.
No takes yet. Share an insight, caveat, or question.
Lajos et al. (2026) conducted a case report in Non-obstructive hypertrophic cardiomyopathy (n=1). Subcutaneous implantable cardioverter-defibrillator (S-ICD) with SMART Pass algorithm was evaluated on Detection of asystole. An S-ICD SMART Pass algorithm deactivation successfully recorded a 22-second asystole causing syncope in a patient with non-obstructive hypertrophic cardiomyopathy, highlighting its potential as an indicator of bradyarrhythmia.
Synapse has enriched 10 related papers. Consider them for comparative context: